Cargando…

CGRP-monoclonal antibodies and SARS-CoV-2 vaccination

Detalles Bibliográficos
Autores principales:	Schiano di Cola, Francesca, Caratozzolo, Salvatore, Liberini, Paolo, Padovani, Alessandro, Rao, Renata
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Letter to the Editors
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742562/ https://www.ncbi.nlm.nih.gov/pubmed/34999961 http://dx.doi.org/10.1007/s00415-021-10946-3

Ejemplares similares

CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
por: Schiano di Cola, Francesca, et al.
Publicado: (2022)

Response Predictors in Chronic Migraine: Medication Overuse and Depressive Symptoms Negatively Impact Onabotulinumtoxin-A Treatment
por: Schiano di Cola, Francesca, et al.
Publicado: (2019)

Onabotulinumtoxin-a during COVID-19 pandemic: Long-term efficacy in chronic migraine
por: Locatelli, Martina, et al.
Publicado: (2021)

Photophobia and migraine outcome during treatment with galcanezumab
por: Schiano di Cola, Francesca, et al.
Publicado: (2023)

Migraine Disability Improvement during Treatment with Galcanezumab in Patients with Chronic and High Frequency Episodic Migraine
por: di Cola, Francesca Schiano, et al.
Publicado: (2023)

Post COVID-19 vaccination headache: A clinical and epidemiological evaluation
por: Ceccardi, Giulia, et al.
Publicado: (2022)

Refractory migraine profile in CGRP‐monoclonal antibodies scenario
por: Silvestro, Marcello, et al.
Publicado: (2021)

Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
por: Tso, Amy R., et al.
Publicado: (2017)

Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine
por: Berman, Gary, et al.
Publicado: (2020)

Change of CGRP Plasma Concentrations in Migraine after Discontinuation of CGRP-(Receptor) Monoclonal Antibodies
por: Raffaelli, Bianca, et al.
Publicado: (2023)

Understanding side-effects of anti-CGRP and anti-CGRP receptor antibodies
por: Haanes, Kristian Agmund, et al.
Publicado: (2020)

“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
por: Martelletti, Paolo
Publicado: (2020)

Inflammatory complications of CGRP monoclonal antibodies: a case series
por: Ray, Jason C., et al.
Publicado: (2021)

Spotlight on Anti‐CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date
por: Pellesi, Lanfranco, et al.
Publicado: (2017)

Monoclonal Antibodies Targeting CGRP: A Novel Treatment in Vestibular Migraine
por: Lovato, Andrea, et al.
Publicado: (2023)

Advances in CGRP Monoclonal Antibodies as Migraine Therapy: A Narrative Review
por: Aditya, Suruchi, et al.
Publicado: (2023)

What to do with non-responders to CGRP(r) monoclonal antibodies: switch to another or move to gepants?
por: Waliszewska-Prosół, Marta, et al.
Publicado: (2023)

Monoclonal Antibodies against SARS-CoV-2: Potential Game-Changer Still Underused
por: Gentile, Ivan, et al.
Publicado: (2021)

Humoral and T cell Responses to SARS-CoV-2 Vaccine Booster and Anti-SARS-CoV-2 Monoclonal Antibodies in Patients With End-Stage Kidney Disease
por: Zaza, Gianluigi, et al.
Publicado: (2023)

Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study
por: Vernieri, Fabrizio, et al.
Publicado: (2021)

CGRP in migraine
por: Tfelt-Hansen, Peer, et al.
Publicado: (2009)

In vitro characterization of AA71, a potent and selective human monoclonal antibody against CGRP receptor
por: Shi, L, et al.
Publicado: (2013)

CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta‐analysis
por: Han, Lin, et al.
Publicado: (2019)

CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
por: Vandervorst, Fenne, et al.
Publicado: (2021)

Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
por: Simioni, Caio Vinicius de Meira Grava
Publicado: (2022)

It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
por: Kubota, Gabriel Taricani
Publicado: (2022)

New Trends in Migraine Pharmacology: Targeting Calcitonin Gene–Related Peptide (CGRP) With Monoclonal Antibodies
por: Scuteri, Damiana, et al.
Publicado: (2019)

Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
por: Sevivas, Hugo, et al.
Publicado: (2022)

Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine
por: Ailani, Jessica, et al.
Publicado: (2021)

OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine
por: Argyriou, Andreas A., et al.
Publicado: (2022)

A Scoping Review and Meta-Analysis of Anti-CGRP Monoclonal Antibodies: Predicting Response
por: Hong, Ja Bin, et al.
Publicado: (2023)

EHMTI-0315. AMG 334, the first potent and selective human monoclonal antibody antagonist against the CGRP receptor
por: Xu, C, et al.
Publicado: (2014)

Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients
por: Barbanti, Piero, et al.
Publicado: (2022)

Can Monoclonal Antibodies against CGRP Offer New Treatment Options for Type 2 Diabetes?
por: Riera, Celine E
Publicado: (2020)

Efficacy of anti–SARS-CoV-2 monoclonal antibody prophylaxis and vaccination on the Omicron variant of COVID-19 in kidney transplant recipients
por: Bertrand, Dominique, et al.
Publicado: (2022)

Safety of Monoclonal Antibodies in Children Affected by SARS-CoV-2 Infection
por: Romani, Lorenza, et al.
Publicado: (2022)

CGRP and CGRP receptors in human and rhesus monkey cerebellum
por: Eftekhari, S, et al.
Publicado: (2013)

A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody
por: Kielbasa, William, et al.
Publicado: (2019)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers
por: Monteith, David, et al.
Publicado: (2017)

Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy
por: Mullin, Kathleen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_sji48f8jmllp2be13sa5il27rl